Analysts Have Conflicting Sentiments on These Healthcare Companies: Certara (CERT), Lantheus (LNTH) and Mirum Pharmaceuticals (MIRM)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Certara (CERT – Research Report), Lantheus ...
Handelsbanken Fonder AB Buys 5,500 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Handelsbanken Fonder AB raised its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 15.4% in the fourth quarter, according to the company in its most recent disclosure ...
FiercePharma3d
Arrowhead, Zevra fire up campaigns for Rare Disease Day 2025
Zevra used the awareness day to roll out the “Learn NPC, Read Between the Signs” disease awareness campaign. The biotech won ...
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) marks Rare Disease Day with the expansion of the We’ll Get There Soon campaign ...
EurekAlert!5d
Decoding the link between colorectal cancer risk and steatotic liver disease
Alcoholic and non-alcoholic fatty liver disease (NAFLD) are well-known risk factors for colorectal cancer (CRC). NAFLD has ...
Rhumbline Advisers Grows Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Rhumbline Advisers raised its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 2.1% in the fourth ...
Arrowhead presents preclinical results on ARO-ALK7
ALK7, the company’s investigational RNA interference therapeutic targeting Activin receptor-like kinase 7 being developed as a potential treatment for obesity. The results were presented in a poster ...
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutic targeting Activin receptor-like kinase ...